EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Timing of Adjuvant Imatinib Initiation and Recurrence‐Free Survival After Curative Resection for Intermediate‐ and High‐Risk Gastrointestinal Stromal Tumors: A Multicenter Real‐World Cohort Study

Zhiming Cai, Huimei Lin, Zihan Lin, Huibin Liu, Jinhu Chen iD, Shichai Hong, Weibin Song, Yanchang Xu, Zhenrong Yang, Yongjian Zhou

International Journal of Cancer · 01.01.2027 · 160 (1) · 149-160

DOI: 10.1002/ijc.70669 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, online erschienen am 24.07.2026. Verfasst von Zhiming Cai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Imatinib Mesylate, Neoplasm Recurrence, Local, Antineoplastic Agents. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Talent Research Project of the First Affiliated Hospital of Fujian Medical University, Fujian Provincial Science and Technology Guided Project, Fujian Provincial Health Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adjuvant imatinib reduces recurrence risk after curative resection for intermediate‐ and high‐risk gastrointestinal stromal tumors, but the optimal timing of postoperative initiation remains unclear. This multicenter real‐world cohort study evaluated 596 patients with modified National Institutes of Health intermediate‐ or high‐risk gastrointestinal stromal tumors who underwent R0 resection followed by adjuvant imatinib therapy at five centers in China. Postoperative imatinib initiation timing was modeled as a continuous variable using a multivariable restricted cubic spline Cox model, and the derived threshold was further evaluated using propensity score overlap weighting. The lowest recurrence risk occurred at 6.22 weeks after surgery, with a 95% confidence interval of 1.29–7.65 weeks; therefore, 8 weeks was selected as a clinically interpretable threshold. After overlap weighting, baseline covariates were well balanced between the planned initiation group (≤ 8 weeks, n = 476) and delayed initiation group (> 8 weeks, n = 120). Delayed initiation was associated with worse 5‐year recurrence‐free survival (70.8% vs. 82.4%) and remained independently associated with an increased risk of recurrence‐free survival events in weighted analysis. Severe postoperative complications were independently associated with delayed initiation. These findings suggest that unnecessary delays in adjuvant imatinib initiation should be minimized once postoperative recovery permits and support timely transition to adjuvant targeted therapy as part of postoperative gastrointestinal stromal tumor management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal Stromal TumorsImatinib MesylateNeoplasm Recurrence, LocalAntineoplastic AgentsGastrointestinal NeoplasmsHumansFemaleMaleChemotherapy, AdjuvantMiddle AgedAgedDisease-Free SurvivalTime FactorsCohort StudiesAdult

Stichwörter der Autor:innen

adjuvant imatinib therapygastrointestinal stromal tumorinitiation timingoverlap weightingrecurrence‐free survival

Substanzen

Imatinib MesylateAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Department of Gastrointestinal Surgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Department of Anorectal Surgery, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, China.
  • Department of Gastrointestinal Surgery, The Affiliated Hospital of Putian University, Putian, China.
  • Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
  • Department of Gastrointestinal Surgery, The First Hospital of Putian City, Putian, China.

ORCID-Profile: Jinhu Chen

Förderung

  • Talent Research Project of the First Affiliated Hospital of Fujian Medical University
  • Fujian Provincial Science and Technology Guided Project
  • Fujian Provincial Health Technology Project

Zitieren

APA

Cai, Z., Lin, H., Lin, Z., Liu, H., Chen, J., Hong, S., Song, W., Xu, Y., Yang, Z., & Zhou, Y. (2027). Timing of Adjuvant Imatinib Initiation and Recurrence‐Free Survival After Curative Resection for Intermediate‐ and High‐Risk Gastrointestinal Stromal Tumors: A Multicenter Real‐World Cohort Study. International Journal of Cancer, 160(1), 149-160. https://doi.org/10.1002/ijc.70669

Vancouver

Cai Z, Lin H, Lin Z, Liu H, Chen J, Hong S, et al. Timing of Adjuvant Imatinib Initiation and Recurrence‐Free Survival After Curative Resection for Intermediate‐ and High‐Risk Gastrointestinal Stromal Tumors: A Multicenter Real‐World Cohort Study. International Journal of Cancer. 2027;160(1):149-160. doi:10.1002/ijc.70669

BibTeX
@article{Cai2027,
  author = {Cai, Zhiming and Lin, Huimei and Lin, Zihan and Liu, Huibin and Chen, Jinhu and Hong, Shichai and Song, Weibin and Xu, Yanchang and Yang, Zhenrong and Zhou, Yongjian},
  title = {Timing of Adjuvant Imatinib Initiation and Recurrence‐Free Survival After Curative Resection for Intermediate‐ and High‐Risk Gastrointestinal Stromal Tumors: A Multicenter Real‐World Cohort Study},
  journal = {International Journal of Cancer},
  year = {2027},
  volume = {160},
  number = {1},
  pages = {149--160},
  doi = {10.1002/ijc.70669}
}
Kostenlos starten →